An 8.26M-share stake in Viridian Therapeutics (VRDN) spans a fund and separately managed accounts.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Paradigm BioCapital Advisors LP, its general partner, and Senai Asefaw, M.D., have reported a beneficial ownership of 8,257,672 common shares (7.3%) in Viridian Therapeutics (VRDN) as of September 30, 2026. This stake includes shares held by Paradigm BioCapital International Fund Ltd., which independently reported 7,278,105 shares (6.4%).
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.